In this article, we will look at 5 best international stocks to invest in. If you want to explore similar stocks, you can take a look at 10 Best International Stocks to Invest In.
5. BioNTech SE (NASDAQ:BNTX)
Number of Hedge Fund Holders: 29
BioNTech SE (NASDAQ:BNTX) is a leading European biotechnology company based in Germany. The company develops and manufactures active immunotherapies for cancer and other infectious diseases. On July 19, Pfizer (PFE) and BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) announced that they have successfully submitted an Omicron-adapted bivalent COVID-19 vaccine candidate, for individuals 12 years of age and older, to the European Medicines Agency.
On July 27, BioNTech SE (NASDAQ:BNTX) announced that it is working with Pfizer Inc. (NYSE:PFE) on a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 microgram dose level. Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) plan to evaluate this next-generation COVID-19 vaccine candidate as part of their efforts to develop a long-term, effective, and robust COVID-19 vaccine.
The market sentiment around BioNTech SE (NASDAQ:BNTX) is positive, and the stock is also trading at bargain levels. On July 13, SVB Securities analyst Daina Graybosch maintained her price target of $223 on BioNTech SE (NASDAQ:BNTX) and upgraded the stock to Outperform from Market Perform. As of August 3, BioNTech SE (NASDAQ:BNTX) has a price-to-earnings ratio of 3.53.
Hedge funds are initiating positions in BioNTech SE (NASDAQ:BNTX). At the end of the first quarter of 2022, 29 hedge funds were eager on BioNTech SE (NASDAQ:BNTX) with stakes worth $409.02 million in the company. This is compared to 27 positions in the previous quarter with stakes worth $644.54 million.
As of March 31, D E Shaw owns over 0.6 million shares of BioNTech SE (NASDAQ:BNTX) and is the largest shareholder in the company. The fund raised its stakes by 114% in the company in Q1 2022, bringing them to $102.96 million.